219O Safety and preliminary efficacy of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the phase 1/2 CheckMate-040 study

Ignacio Melero(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Bruno Sangro(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Tung On Yau(Chinese University of Hong Kong), C-H. Hsu(National Taiwan University Hospital), M. Kudo(Kindai University), Todd S. Crocenzi(Providence Portland Medical Center), T.-Y. Kim(Seoul National University Hospital), Su Pin Choo(National Cancer Centre Singapore), Jörg Trojan(Goethe University Frankfurt), Tim Meyer(The Royal Free Hospital), T.H. WellingIII(University of Michigan), Winnie Yeo(Chinese University of Hong Kong), A. Chopra, J. Anderson(Bristol-Myers Squibb (United States)), Christine Delacruz(Bristol-Myers Squibb (United States)), L. Láng(Bristol-Myers Squibb (United States)), Jaclyn Neely(Bristol-Myers Squibb (United States)), A. El-Khoueiry(University of Southern California)
Annals of Oncology
December 1, 2016
Cited by 4Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis